Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LHW090 renal safety and pharmacokinetics study in moderate renal impairment on angiotensin receptor blockers
2015-004570-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing LHW090 with Placebo (2 arms). Primary endpoints: Safety endpoints, Pharmacokinetic parameters and 1 more. Started Apr 2017; status: completed.
02
Drugs
LHW090
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2015-004570-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004570-15.